|
Target Audience
Psychiatrists
Learning Objectives
-
Based on relevant guidelines, you will be able to consider and
explain the benefits and risks of stimulant use in adolescent and adult
patients—with and without pre-existing cardiovascular conditions—to create an
optimized treatment plan.
-
You will be able to evaluate the risks for abuse, misuse, and
diversion of medications for ADHD and to discuss and apply this information when
considering treatment options for your adolescent and adult patients with ADHD.
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
Veritas Institute for Medical Education, Inc. designates this educational
activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should
only claim credit commensurate with the extent of their participation in the
activity.
Financial Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME
providers are required to disclose to the activity audience the relevant
financial relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial relationship
if he or she has a financial relationship in any amount occurring in the last 12
months with a commercial interest whose products or services are discussed in
the CME activity content over which the individual has control. Disclosures are
as follows:
James J. McGough, MD―Eli Lilly and Company; McNeil
Consumer and Specialty Products, a Division of McNeil-PPC, Inc; Novartis
Pharmaceuticals Corporation; Shire (grant/research support, speakers bureau,
and/or consultant).
Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc,
Eli Lilly and Company, Janssen Pharmaceutica Products LP, National Institute of
Mental Health, National Institute on Drug Abuse, Neurosearch, Novartis
Pharmaceuticals Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research
support, speakers bureau, and/or consultant).
The staff of Veritas Institute for Medical Education, Inc. has
nothing to disclose.
Unlabeled Use Disclosure Statement
Participants are advised that this CME activity will contain references to
unlabeled/unapproved/ investigational uses of guanfacine, clonidine,
methylphenidate, amphetamine compounds, and atomoxetine.
Method of Participation
Listen to the prerecorded telesymposium and complete the Posttest, Activity
Evaluation, and Request for Credit Form. You will receive your CME certificate
immediately. This activity is provided free of charge to participating
physicians.
|
Safety Issues in Managing ADHD in Adolescents
Transitioning to Adulthood
James J. McGough, MD
Release Date: March 2007
Expiration Date: February 29, 2008
At the end of the audio presentation, you
will be given a passcode. Please
enter it in the space below to access the post-test, activity evaluation,
and request for credit form.
 |